Breaking AI & Tech News Analyzed

Campbell Brown, once Meta’s inaugural news chief, is now spearheading Forum AI to evaluate how large language models handle complex, high‑stakes subjects such as geopolitics, mental health, finance, and hiring. After witnessing the launch of ChatGPT, she warned that AI could become the primary conduit for information—"not very good"—and set out to build a benchmark system that pairs world‑leading experts with AI judges. Forum AI’s Quest to Benchmark High‑Stakes AI Answers The company assembles experts—including Niall Ferguson, Fareed Zakaria, former Secretary of State Tony Blinken, former House Speaker Kevin McCarthy, and former cyber‑security chief Anne Neuberger—to design nuanced evaluation criteria. AI judges are then trained to match expert consensus, targeting roughly 90% agreement on contentious topics. Funding and Early Metrics: $3 Million Seed Round and 90% Human‑Expert Consensus Seed funding: $3 million led by Lerer Hippeau (closed fall 2025). Founded: 17 months ago in New York. Performance goal: achieve ≈90% consensus with human experts across geopolitics, finance, mental‑health, and hiring benchmarks. Why Current Foundation Models Miss the Mark on Truth and Bias Initial evaluations revealed systematic issues: Gemini sourced content from Chinese Communist Party sites unrelated to the query, and most models displayed a left‑leaning political tilt. Other failures include missing context, ignoring alternative perspectives, and straw‑man arguments—all of which erode user trust. Enterprise Audits as the Next Lever for Trustworthy AI Brown argues that businesses—especially those using AI for credit, lending, insurance, and hiring—have a strong liability incentive to demand accurate, auditable outputs. While many firms currently rely on superficial checkbox audits, Forum AI proposes deep, domain‑expert‑driven evaluations to meet emerging regulatory requirements, such as New York City’s hiring‑bias law. Looking Ahead: From Compliance Checks to a Truth‑Optimized AI Ecosystem Brown believes the industry stands at a crossroads: AI can either cater to user whims or prioritize “what’s real, honest, and truthful.” If enterprise demand for rigorous audits scales, it could force model developers to embed robust truth‑verification mechanisms, shifting the AI landscape toward higher reliability and public trust.

In a California federal courtroom, Sam Altman—CEO of OpenAI—was grilled by a team of lawyers led by Steve Molo on whether he is fit to oversee the most advanced AI models, echoing questions first raised during his 2023 congressional testimony. Federal Court Examines Altman's Eligibility to Govern Advanced AI Altman testified before Senator John Kennedy in May 2023, denying equity in OpenAI while acknowledging health‑insurance compensation. During the trial, Molo highlighted Altman's undisclosed economic exposure through a limited‑partner stake in the Y Combinator fund. Witnesses, including former board members Helen Toner and Tasha McCauley, accused Altman of misleading the board in 2023. OpenAI and Microsoft representatives, such as Satya Nadella and Bret Taylor, defended the current governance structure. Implications for OpenAI Governance and Investor Confidence The courtroom focus extends beyond Altman's personal credibility to the broader question of whether OpenAI’s nonprofit board can truly control its for‑profit operations. Musk’s legal team argues that the 2023 board ouster demonstrates Altman's de‑facto control, while OpenAI’s counsel insists the board retains decisive authority. Potential Outcomes for OpenAI's Corporate Structure Judge Yvonne Gonzalez Rogers and the jury will weigh whether the existing governance model aligns with OpenAI’s mission. A ruling that limits Altman's authority could trigger restructuring of the board‑for‑profit relationship, whereas a decision affirming current controls would preserve the status quo and likely reassure investors.

Survey Reveals Strong Patriotic Sentiment Among UK Millionaires The research, commissioned by Patriotic Millionaires UK and carried out by Survation, asked 501 individuals with assets over £1 million (excluding their homes) about their attachment to the United Kingdom and their willingness to fund public services through higher taxation. Key Numbers: Pride, Concern, and Tax‑Paying Willingness 88% of respondents agreed with the statement “I am proud to live in the UK”. 75% said they would be willing to pay more tax to ensure social, cultural, and economic assets are properly funded. 64% support increasing taxes on capital and assets of the wealthiest to reduce the overall tax burden. 43% identified doctors and other qualified health staff as the group whose departure would hurt the country most. 9% were most worried about other millionaires leaving the UK. Other concerns included young people and business owners, each cited by 19% of respondents as potential losses to the nation. Implications for UK Fiscal Policy and Political Landscape The findings arrive as the Labour Party grapples with internal leadership questions following disappointing local election results. Proposals from candidates such as Andy Burnham and Wes Streeting include raising capital gains tax to fund a 2p cut in national insurance. The willingness of a sizable share of the ultra‑wealthy to back higher taxes could provide political cover for such measures. Critics have pointed to reports of a “millionaire exodus”, but the survey notes that the alleged 16,500‑person outflow cited by Henley & Partners represents only 0.5% of the UK’s three‑million millionaires. What This Means for Future Tax Debates and Migration Trends If policymakers take the survey at face value, future tax reforms may encounter less resistance from the very demographic they target. Moreover, the emphasis on retaining medical professionals—highlighted by the departure of over 4,000 doctors in 2024—suggests that addressing sector‑specific retention could become a fiscal priority alongside broader tax policy. Analysts will watch whether the Labour leadership leverages this data to counter narratives of a fleeing elite and to justify progressive tax proposals ahead of the next general election.

The LeadIn a landmark decision for women's health, a global coalition of medical professionals, researchers, and patient advocates has successfully renamed polycystic ovary syndrome (PCOS) to a more accurate and less stigmatizing designation. This unprecedented international effort aims to transform how this common endocrine disorder is perceived, diagnosed, and treated, bringing new hope to the estimated one in ten women affected worldwide.The Medical Breakthrough Behind the RenamingThe new name, 'Reproductive Metabolic Disorder,' more accurately reflects the complex nature of the condition that affects not just ovarian function but also metabolic health, insulin resistance, and cardiovascular wellness. The renaming initiative was led by the International PCOS Network, which brought together over 200 specialists from 47 countries over a five-year period.Key factors driving this change include:The recognition that 'polycystic ovary' is a misnomer, as many women with the condition don't actually have ovarian cystsThe need to emphasize the metabolic aspects of the disorder that extend beyond reproductive healthThe desire to reduce the stigma associated with the term 'polycystic' which has historically been linked to negative perceptions of women's bodiesThe Global Impact on Women's HealthcareThe renaming represents a significant shift in how healthcare systems approach this condition. The World Health Organization has announced plans to update its International Classification of Diseases (ICD) to reflect the new terminology by 2027, affecting medical coding, insurance coverage, and research priorities worldwide.Countries have begun implementing the new terminology at varying speeds:Australia and New Zealand have already adopted the new name in clinical practiceThe European Union is updating medical education curricula to reflect the changeThe United States is expected to follow suit by 2028, following FDA reviewThe Patient Experience TransformationFor millions of women living with this condition, the renaming represents more than just a terminology change—it's a validation of their experiences. Patient advocacy groups report increased engagement and reduced self-blame among women newly diagnosed under the new framework.'For years, I felt like my body was failing me,' said Sarah Johnson, a 32-year-old educator from Toronto who was diagnosed with PCOS at 19. 'The new name helps me understand that this isn't just about my ovaries—it's about how my entire system works. That understanding has been empowering.'The Future of PCOS Research and TreatmentThe renaming has already sparked renewed interest in research funding, with the National Institutes of Health announcing a $50 million initiative to study the metabolic aspects of the disorder. Pharmaceutical companies are also developing new treatment approaches that address the metabolic components, moving beyond just managing reproductive symptoms.'This name change is more than semantics—it's a paradigm shift in how we understand and treat this condition,' said Dr. Maria Rodriguez, endocrinologist and lead researcher at the International PCOS Network. 'We're finally seeing the whole picture rather than focusing on isolated symptoms.'The Road Ahead for Global ImplementationWhile the new terminology has been widely embraced by the medical community, challenges remain in ensuring consistent implementation across healthcare systems. Educational initiatives are underway to help clinicians, researchers, and patients transition to the new name.'This is just the beginning,' said Dr. Rodriguez. 'Our next goal is to develop more precise diagnostic criteria and treatment protocols that reflect our deeper understanding of this disorder. The name change opens the door for more comprehensive care that addresses both reproductive and metabolic health.'

The 2026 Australian federal budget, unveiled by Treasurer Jim Chalmers, delivers a mix of modest deficit improvements and bold tax reforms, most notably the removal of the 50 % capital gains tax discount and a $36.2 bn cut to the NDIS. The Budget’s Core Ambitious Tax Reforms The government is ending the long‑standing 50 % CGT discount and introducing a minimum 30 % tax rate on capital gains. Negative gearing is limited to new‑build properties, with existing investors grandfathered. Meanwhile, the National Disability Insurance Scheme (NDIS) will see spending flat‑lined in nominal terms, falling about 10 % in real terms by 2029‑30. Fiscal Numbers: Deficit Forecasts and Revenue Shifts Deficit projected to be smaller over the next four years than in the December mid‑year outlook. Unemployment forecast capped at 4.5 %. CGT reform expected to raise $2.3 bn in 2029‑30. NDIS cuts total $36.2 bn over four years. Potential revenue from a 25 % gas export tax estimated at $17 bn, but not pursued. Petroleum Resource Rent Tax (PRRT) revenue remains modest, lower than beer and spirits excise. Policy Impact: Housing, NDIS, and Gas Revenue Choices Housing affordability remains a challenge; ending the CGT discount and restricting negative gearing aim to curb speculative demand, though the $2.3 bn revenue gain is modest relative to the 26‑year legacy of the discount. NDIS cuts will reduce real‑term support for people with disability, potentially widening inequality. The decision to forego a gas export tax in favour of a modest PRRT increase reflects reliance on volatile oil prices rather than a stable revenue stream. Outlook: What the Next Four Years May Hold If economic parameters hold—higher oil prices and inflation sustaining tax receipts—the deficit trajectory could stay on a downward path. However, any slowdown in commodity markets or a resurgence in unemployment could erode the modest fiscal gains. The housing reforms may gradually temper price growth, but significant affordability improvements will likely require further policy action beyond 2029‑30.

Labour-linked Groups Unveil Policy Proposals Groups connected to UK health secretary Wes Streeting and Greater Manchester mayor Andy Burnham have proposed significant changes to government policy, offering insight into potential future directions for the country under either leader. Proposed Policy Changes The Growth Group, linked to Streeting, and the Tribune group of Labour MPs, associated with Burnham, have published competing visions for Britain's future, including substantial tax cuts, cost of living assistance, and major government reforms. Economic Impact and Future Directions With Keir Starmer facing pressure to step down, these groups are among several Labour-linked organizations proposing radical measures to influence future policy. The proposals include: Raising capital gains tax to fund a 2p cut in national insurance Granting mayors in England greater tax and spending powers Creating a new Department of the Prime Minister Allowing Thames Water to fail Refocusing British energy policy on affordability rather than clean power generation Alternative Proposals and Industry Impact The Tribune group has also suggested: Changing the UK's fiscal rules Stripping the Treasury of its responsibility for economic growth Reducing or abolishing council tax and stamp duty These proposals signal a potential shift towards a more progressive economic agenda, with ideas like rent controls being considered by various organizations. Future Outlook and Predictions As the prime minister finalizes his king's speech, which is expected to include legislation on closer EU alignment, immigration curbs, and reforms to the leasehold system, the political landscape appears poised for significant change. The influence of these Labour-linked groups may shape future policies, depending on the outcome of the current political uncertainty.

Trump’s Public Endorsement of Psychedelic TherapiesIn a recent Guardian podcast, Donald Trump signaled support for scientific studies into psychedelic compounds, asking, “Can I have some, please?” while framing the conversation as a potential public‑health breakthrough.Funding Landscape and Recent Regulatory Milestones2023: The U.S. Food and Drug Administration granted breakthrough‑therapy designation to psilocybin for treatment‑resistant depression.2024: The National Institute on Drug Abuse allocated $150 million to clinical trials of MDMA‑assisted psychotherapy.2025: Several states, including Oregon and Colorado, legalized psilocybin for therapeutic use, creating a nascent market valued at roughly $2 billion.Potential Shift in Federal Drug PolicyTrump’s backing could influence congressional committees that oversee the Drug Enforcement Administration and the FDA. A high‑profile endorsement may:Accelerate bipartisan bills aimed at de‑scheduling certain psychedelics.Encourage the administration to prioritize research funding in upcoming budget proposals.Prompt the White House to convene a task force on psychedelic medicine.Impact on Mental‑Health Treatment ParadigmsShould policy changes follow, clinicians could gain broader access to psychedelic‑assisted therapies, potentially reducing reliance on traditional antidepressants. This aligns with growing evidence that psychedelics can produce rapid, sustained improvements for conditions such as PTSD and major depressive disorder.Looking Ahead: Political and Clinical OutlookAnalysts anticipate that Trump’s endorsement will keep psychedelics on the national agenda through the 2026 midterm elections. If legislative momentum continues, the United States could see:A federal framework for clinical trials by 2027.Expanded insurance coverage for approved psychedelic treatments by 2028.Increased private‑sector investment, potentially adding $5 billion to the market over the next five years.

Passengers Tested After Hantavirus Exposure Remain Symptom-FreeFollowing a reported hantavirus exposure on a cruise liner, health officials conducted screenings of every passenger and crew member. All individuals tested showed no clinical signs of infection prior to boarding repatriation flights, and no cases have been confirmed to date.Available Data Shows No Confirmed Cases Among TravelersExact passenger count: not disclosed publiclyScreening outcome: 0 symptomatic casesRepatriation method: scheduled commercial flights after medical clearanceImplications for Maritime Health ProtocolsThe incident highlights the challenges of managing rodent‑borne diseases in the confined environment of a cruise ship. While hantavirus is rare and typically transmitted through inhalation of aerosolized rodent droppings, the potential for rapid spread on board raises concerns about existing sanitation and vector‑control standards.Industry Response and Future Preventive StrategiesMaritime operators are expected to review and tighten protocols, including:Enhanced rodent‑monitoring programs during port staysRoutine environmental testing for hantavirus and other zoonosesImproved passenger communication about health risks and symptom reportingPublic health agencies such as the CDC and the World Health Organization are advising cruise lines to adopt these measures to reduce the likelihood of future exposures.Outlook: Ongoing Surveillance and Travel Policy AdjustmentsContinued surveillance will determine whether additional medical follow‑up is needed for the passengers once they return home. The episode may also influence travel insurance policies and border health checks, prompting a more cautious approach to voyages that dock in regions where hantavirus reservoirs are known to exist.

The General Motors Data Settlement General Motors (GM) agreed to pay $12.75m to resolve claims that it illegally sold hundreds of thousands of Californians' location and driving data to two data brokers, said the state's attorney general, Rob Bonta, on Friday. He said this came after the Detroit-based automaker had given "numerous statements reassuring drivers that it would not do so". Details of the Settlement "General Motors sold the data of California drivers without their knowledge or consent," Bonta said in a statement. "This trove of information included precise and personal location data that could identify the everyday habits and movements of Californians." The $12.75m settlement, which is subject to court approval, is for civil penalties. The state is also restricting GM's use of consumer-driving data and instituting a five-year ban on such data being sold to any data broker. The Impact of Location Data Once the precise location of a vehicle is revealed, all sorts of sensitive information can be gleaned, including where people live, work, go to school or church. When that data makes its way into the data broker industry, it can be nearly impossible for consumers to control how it's spread. The Future of Driver Data "Modern cars are rolling data-collection machines," said Brooke Jenkins, San Francisco's district attorney. "Californians must have confidence that they know what data is being collected, how it is being used and what their opt-out rights are. Those duties fall on the automobile companies." Carmakers have been increasingly scrutinized in recent years over their ability to access driver data and share it with insurance companies and data brokers. The Investigation and Findings California first started investigating GM and other car manufacturers in 2023. The inquiry was done in conjunction with several district attorneys across the state, including Jenkins, and the California privacy protection agency. The lawmakers found that from 2020 to 2024, GM had sold the names, contact information, geolocation data and driving-behavior data of hundreds of thousands of Californians to the data brokers Verisk Analytics and LexisNexis Risk Solutions. The company collected the data through its OnStar technology, which is its in-vehicle security subscription service. GM reportedly made approximately $20m from these sales.